Diabetic Macular Oedema, Macular Degeneration, Retina/Vitreous
Read Time: 2 mins

Macular Pigment Optical Density in Macular Health and Visual Function

Copy Link
Published Online: Aug 5th 2012 European Ophthalmic Review, 2012;6(4):227-9 DOI:
Authors: Samanta Maci
Quick Links:
Article Information

Extensive research has described the biological and optical characteristics of the macular pigment (MP) and has confirmed its composition and dietary origin. Epidemiological and intervention trials support the protective role of MP in the retina as well as its positive effects on visual function in healthy individuals in addition to patients with age-related macular degeneration (AMD). The amount of MP in the macula can be assessed by measuring a surrogate optical indicator, macular pigment optical density (MPOD). New evidence from recently published clinical trials and a European consensus roundtable have confirmed that MPOD can be increased by increasing the ingestion of lutein and zeaxanthin and that MPOD increase benefits macular health and visual function. On balance, this recent evidence suggests a critical role of MP in eye health as well as the importance of assessing if adequate levels of the dietary macular carotenoids are regularly consumed in order to ensure proper availability for deposition into the macula.


Lutein, zeaxanthin, macular pigment, MPOD, AMD, visual function


In 1945, Wald reported that the macula lutea of humans and certain other primates contains a yellow pigment and suggested that this macular pigment (MP) was a carotenoid. By analysing the spectral sensitivity of the human foveal and peripheral photoreceptors, he estimated the light absorbed/transmitted by the macular pigment, and used the term macular pigment optical density (more recently associated with the acronym MPOD). At the same time he observed a great variation in the intensity of macula pigmentation among subjects – from foveas with no perceptible pigmentation to very intense coloured ones.1 Research conducted in recent decades has confirmed that the MP is composed by three distinct carotenoids lutein (L), zeaxanthin (Z) and meso-zeaxanthin (MZ).2,3 MP reaches highest concentration (per mm2 of tissue) at the centre of the fovea decreasing rapidly with distance from the epicentre. The concentrations of L, Z and MZ also vary with eccentricity – in the adult retina, while the three macular carotenoids are present in similar concentrations at foveal centre, as the eccentricity from the fovea increases, lutein becomes the predominant pigment with a decreasing amount of Z, and with MZ, approaching undetectable levels.3 The role of the MP in the human eye is well described and is based on the biological and optical characteristics of its main components.4–7 It acts as an antioxidant by quenching reactive oxygen species and as a filter for damaging high energy/short-wavelengths of visible light (blue light). These functions support the protective role of the MP in the retina, a tissue particularly susceptible to oxidative stress and the more recently explored beneficial effects on visual function.

Macular Pigment Optical Density and the Diet
Studies conducted in monkeys raised on a xanthophyll-free diet from birth have shown that the macular pigment is of dietary origin and that L and Z supplementation can replenish the macular pigment. Moreover, those results indicate that, while the accumulation of L and Z in serum and retina stems from the ingestion of these two xanthophylls with the diet, MZ originates exclusively from the conversion of L in the macula. MZ is not present in serum.8,9 Additional observations conducted in thesexanthophyll-free animals indicate the presence of drusen in the igment epithelium.8 A recent publication addressed the effect of acute blue-light exposure in xanthophyll-free animals lacking the macular pigment in comparison to control animals fed stock diet containing xanthophylls.10 The presence of the macular pigment rendered control animals less susceptible to blue light-induced damage in both the fovea and parafovea although more damage was observed in the parafoveal area than in the fovea. The xanthophyll-free animals, who exhibited no MP, experienced similar damage in both the foveal and parafoveal areas resulting from blue-light exposure as well as more damage than control animals. Supplementation of the xanthophyll-free animals with L or Z increased macular pigment density and decreased foveal susceptibility to blue-light induced damage to control levels. In the author’s words, “L and Z when provided in the diet and deposited as macular pigment, provided foveal protection from acute blue-light photochemical damage. It seems probable that these nutrients would also protect the macula against chronic blue-light-induced damage”.

To view the full article in PDF or eBook formats, please click on the icons above.

Article Information:

Samanta Maci is an employee of Kemin.


Samanta Maci, Kemin Human Nutrition and Health, Campo Grande 35- 8ºD, 1700-087 Lisboa, Portugal. E:


The publication of this article was supported by Kemin.




  1. Wald G, Human vision and the spectrum, Science, 1945;101(2635):653–8.
  2. Bone RA, Landrum JT, Tarsis SL, Preliminary identification of the human macular pigment, Vision Res, 1985;25(11):1531–5.
  3. Bone RA, Landrum JT, Friedes LM, et al., Distribution of lutein and zeaxanthin stereoisomers in the human retina, Exp Eye Res, 1997;64(2):211–8.
  4. Krinsky NI, Landrum JT, Bone RA, Biologic mechanisms of the protective role of lutein and zeaxanthin in the eye, Annu Rev Nutr, 2003;23:171–201.
  5. Khachik F, Bernstein PS, Garland DL, Identification of lutein and zeaxanthin oxidation products in human and monkey retinas, Invest Ophthalmol Vis Sci, 1997;38(9):1802–11.
  6. Stahl W, Macular carotenoids: lutein and zeaxanthin, Augustin A (ed): Nutrition and the Eye, Dev Ophthalmol Basel, Karger, 2005;38:70–88.
  7. Bernstein PS, Delori FC, Richer S, et al., The value of measurement of macular carotenoid pigment optical densities and distributions in age-related macular degeneration and other retinal disorders, Vision Research, 2010;50:716–28.
  8. Malinow MR, Feeney-Burns L, Peterson LH, et al., Dietrelated macular anomalies in monkeys. Invest Ophthalmol Vis Sci, 1980;19(8):857–63.
  9. Neuringer M, Sandstrom MM, Johnson EJ, Snodderly DM, Nutritional manipulation of primate retinas: effects of lutein or zeaxanthin supplements on serum and macular pigment in xanthophyll-free rhesus monkeys, Invest Ophthalmol Vis Sci, 2004;45(9):3234–43.
  10. Barker FM, Snodderly D, Johnson EJ, et al., Nutritional manipulation of primate retinas, V: effects of lutein, zeaxanthin, and n-3 fatty acids on retinal sensitivity to blue-light-induced damage, Invest Ophthalmol Vis Sci, 2011 Jun;52(7):3934–42.
  11. Seddon JM, Ajani UA, Sperduto RD, et al., Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. Eye Disease Case-Control Study Group, Jama, 1994;272(18):1413 –20.
  12. Delcourt C, Carriere I, Delage M, et al., Plasma lutein and zeaxanthin and other carotenoids as modifiable risk factors for age-related maculopathy and cataract: the POLA Study, Invest Ophthalmol Vis Sci, 2006;47(6):2329–35.
  13. Bone RA, Landrum JT, Mayne ST, Gomez CM, Tibor SE, Twaroska EE, Macular pigment in donor eyes with and without AMD: a case-control study, Invest Ophthalmol Vis Sci, 2001;42(1):235–40.
  14. Age-Related Disease Study Group, The relationship of dietary carotenoid and vitamin A, E, and C intake with age-related macular degeneration in a case-control study: AREDS Report No. 22, Archives of Ophthalmology, 2007;125(9):1225–32.
  15. Nolan JM, Stack J, O’Donovan O, et al., Risk factors for age-related maculopathy are associated with a relative lack of macular pigment, Experimental Eye Research, 2007;84(1):61–74.
  16. Stringham JM, Hammond BR Jr, The glare hypothesis of macular pigment function, Optometry and Vision Science, 2007. 84(9):859–64.
  17. Stringham JM, Garcia PV, Smith PA, et al., Macular pigment and visual performance in glare: benefits for photostress recovery, disability glare, and visual discomfort, Invest, Ophthalmol, Vis, Sci, 2011;52(10):7406–15.
  18. Richer S, Stiles W, Statkute L, et al., Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial) Optometry, 2004;75(4):216–30.
  19. Stringham JM, Hammond BR, Macular pigment and visual performance under glare conditions, Opthometry and Vision Science, 2008;85(2):82–8.
  20. Jentsch S, Schweitzer D, Hammer M, Dawczynski J, Optische Makulapigmentdichte (MPOD) als protektive Faktor bei der trockenen altersbedingten Makuladegeneration (AMD) - Ergebnisse der LUTEGA-Studie, Presented at: DOG Congress 2011, (abstract #839).
  21. Jentsch S, Schweitzer D, Hammer M, et al., The lutega-study: lutein and omega-3-fatty acids and their relevance for macular pigment in patients with age-related macular degeneration (AMD), Presented at: ARVO 2011 (abstract #624).
  22. Richer S, Stiles W, Graham-Hoffman K, et al., Randomized, double-blind, placebo-controlled study of zeaxanthin and visual function in patients with atrophic age-related macular degeneration, the zeaxanthin and visual function study (ZVF) FDA IND #78, 973, Optometry, 2011;82;667–80.
  23. Piermarocchi S, Saviano S, Parisi V, et al., For the Carmis study group, carotenoids in age-related maculopathy italian study (CARMIS): two-year results of a randomized study, Eur J Ophthalmol, 2011;22(2):216 –225.
  24. Parisi V, Tedeschi M, Gallinaro G, et al., Carotenoids and antioxidants in age-related maculopathy italian study: multifocal electroretinogram modifications after 1 year, Ophthalmology, 2008;115(2):324–33 e2.
  25. Dawczynski J, Optische Makulapigmentdichte und Altersabhängige Makuladegeneration, CME supplement in: Ophthalmologische Nachrichten, 2012 Aug, issue 8.
  26. European Consensus Roundtable, MPOD in macular health and visual function, Frankfurt, Germany, March 14, 2012.
  27. United States Department of Agriculture, What we eat in America, NHANES 2009–2010. Available at: www.ars.usda. gov/Services/docs.htm?docid=18349 (accessed 28 September 2012).
  28. O'Neill ME, Carroll Y, Corridan B, et al., A european carotenoid database to assess carotenoid intakes and its use in a five-country comparative study, Br J Nutr, 2001;85(4):499–507.

Further Resources

Share this Article
Related Content In Retina/Vitreous
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72